Teriparatide vs Abaloparatide: What You Need to Know About Anabolic Agents for Osteoporosis

When bone loss goes beyond prevention

Most people with osteoporosis start with pills that slow bone breakdown-bisphosphonates, denosumab, or similar drugs. But if your bones are already severely weakened, those won’t rebuild what’s been lost. That’s where anabolic agents like teriparatide and abaloparatide come in. These aren’t just more potent versions of older drugs. They’re fundamentally different: they actually trigger your body to make new bone. Think of it like this: antiresorptive drugs are the brakes. Anabolic agents are the gas pedal. If you’ve had multiple fractures, your T-score is below -3.0, or your doctor says you’re at very high risk, this is the next step. Both teriparatide and abaloparatide are daily injections. Both are used for no more than 18 to 24 months. Both are followed by a long-term antiresorptive drug to lock in the gains. But the differences between them? They matter-especially if you’re trying to avoid another fracture or manage side effects.

How teriparatide and abaloparatide work

Teriparatide is a piece of human parathyroid hormone (PTH 1-34). It’s been around since 2002, the first drug of its kind approved by the FDA. Abaloparatide, approved in 2017, is a synthetic copy of a different hormone-PTHrP-that mimics how your body naturally builds bone. The key difference? They bind to the same receptor on bone cells, but in slightly different ways. Abaloparatide prefers the RG conformation of the receptor, which leans more toward bone formation and less toward bone breakdown. Teriparatide activates both sides of the receptor more evenly. That’s why abaloparatide causes less hypercalcemia (high calcium in the blood) and appears to build more bone in the hip. In the ACTIVE trial, abaloparatide reduced new vertebral fractures by 86% compared to placebo. Teriparatide reduced them by about 65%. The hip fracture numbers were even more telling: abaloparatide cut hip fractures by 43% more than teriparatide in a 2024 real-world study of over 43,000 women.

Which one builds more bone?

Bone mineral density (BMD) gains tell part of the story. At 18 months:

• Lumbar spine: Both increase BMD by about 9-10%. Abaloparatide leads slightly at 6 months, but by 18 months, the difference fades.
• Femoral neck: Abaloparatide wins. +2.93% vs +1.49% with teriparatide.
• Total hip: Abaloparatide again leads. +3.41% vs +2.04%.

These numbers aren’t just stats. For someone with a total hip T-score of -2.7, there’s a better than 50% chance they’ll cross the -2.5 threshold (out of osteoporosis range) with either drug. But with abaloparatide, that chance is higher-and the improvement is more consistent across the hip, which is where the most dangerous fractures happen.

Safety: Side effects you can’t ignore

Both drugs can cause dizziness, nausea, and leg cramps. About 1 in 3 people report injection site reactions. But the big difference is hypercalcemia. Teriparatide causes high blood calcium in 6.4% of users. Abaloparatide? Only 3.4%. That’s nearly half the rate. For people with kidney issues, a history of kidney stones, or who are older and more sensitive to calcium shifts, this isn’t a minor detail-it’s a dealbreaker. Real-world patient reports back this up. On osteoporosis forums, users switching from teriparatide to abaloparatide often say their calcium levels normalized within weeks. One Reddit user wrote: “I was getting dizzy and nauseous every day. My doctor said it was the calcium. Switched to abaloparatide-no more issues.” Dizziness is also more common with teriparatide: 41% vs 29% with abaloparatide. That’s a problem if you’re already at risk for falls.

Cost and access

Here’s where things get messy. As of early 2025, teriparatide (now generic) costs about $4,200 per month. Abaloparatide? Still brand-name, around $5,750. That’s a 37% difference. Insurance coverage is a huge barrier. In 2023, 44% of abaloparatide users reported prior authorization denials or high copays. Only 28% of teriparatide users had the same issue. The introduction of generic teriparatide in January 2024 changed the game. By 2025, its price is expected to drop another 40%. That makes teriparatide the clear choice for cost-sensitive patients-especially if their hip T-score isn’t critically low.

Who gets which drug?

There’s no one-size-fits-all answer. But guidelines from the American Association of Clinical Endocrinologists (AACE) in 2023 give clear direction:

• Start with teriparatide if you’re cost-conscious, have no prior hip fractures, and your main concern is spine or general bone density.
• Choose abaloparatide if you have a hip T-score ≤ -3.0, a history of nonvertebral fractures, or you’ve had hypercalcemia on other treatments.

A 2024 retrospective study showed abaloparatide users had a 17% lower risk of hip fracture and a 12% lower risk of any nonvertebral fracture over 18 months. That’s not just statistically significant-it’s clinically meaningful. But Dr. Ethel Siris, a leading osteoporosis expert, has a counterpoint: “The absolute difference in fracture reduction between these two drugs is small. Is the extra cost worth it for most people?” The answer depends on your risk profile. If you’ve already broken a hip or spine, and your doctor says you’re at high risk for another, then yes. If you’re younger, have good insurance, and your T-score is borderline, teriparatide still does the job.

How the treatment works in practice

Both drugs are injected daily under the skin, usually in the thigh or abdomen. They come in pre-filled pens. You need to keep them refrigerated. Most people get used to the routine within a few weeks. The first month is the hardest. About 78% of patients need help with injection technique, timing, or managing dizziness after the shot. Orthostatic hypotension-feeling lightheaded when standing up-is common, especially in the first hour after injection. Most doctors recommend sitting or lying down for 30 minutes after each dose. You won’t see results right away. DXA scans at 6 months show if you’re responding. If your lumbar spine BMD hasn’t increased by at least 3%, your doctor may question whether the drug is working for you.

What happens after 18 months?

Neither drug can be used longer than 24 months. That’s because long-term use may increase the risk of osteosarcoma (a rare bone cancer) in animal studies. We don’t see that in humans, but the FDA still limits use. That’s why the next step matters more than the first. The ACTIVE-EXTEND trial showed that after 18 months of abaloparatide, switching to alendronate (a bisphosphonate) kept the gains. At 3.5 years, 68% of patients kept their total hip T-score above -2.5. Only 52% did if they’d been on placebo then alendronate. The same applies to teriparatide. You don’t stop treatment-you transition. That’s now standard practice. The goal isn’t just to build bone-it’s to keep it.

What’s coming next?

The future of these drugs isn’t just about picking between two daily injections. Radius Health is testing a weekly version of abaloparatide. Phase 3 trials ended in December 2023. Results are expected in late 2025. If approved, that could dramatically improve adherence. The FDA has also signaled it’s open to extending treatment beyond 24 months-something that could change the game for patients with chronic, progressive osteoporosis. Meanwhile, the market is shifting. Teriparatide still leads in sales, but abaloparatide is growing fast. By 2028, anabolic agents are expected to make up 41% of the osteoporosis market, up from 32% today. Why? Because we’re aging. By 2030, 1 in 5 Americans will be over 65. And 10.2 million already have osteoporosis severe enough to need these drugs.

Final thoughts: It’s not about the drug-it’s about the person

Choosing between teriparatide and abaloparatide isn’t about which one is “better.” It’s about which one is better for you. If you’re older, have a history of fractures, high risk of falling, or trouble with calcium levels-abaloparatide’s safety edge and hip benefits make it the stronger choice. If you’re younger, have good insurance, or are trying to minimize out-of-pocket costs-teriparatide still delivers strong results with a proven track record. Either way, this isn’t a lifelong pill. It’s a targeted, time-limited push to rebuild bone before switching to maintenance therapy. And for people who’ve already lost too much, it’s one of the most powerful tools we have.

Frequently Asked Questions